ArticleCurrent medical imaging2026
Preoperative Prediction of Fat-Suppressed T2-Weighted Imaging-based Breast Edema Scores for Lymphovascular Invasion in Patients with Breast Cancer
Article in Current medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLymphovascular invasion (LVI) is a critical prognostic factor in breast cancer, typically diagnosed via postoperative pathology. This study aimed to evaluate whether fat-suppressed T2-weighted imaging (FS T2WI)-based breast edema score (BES) combined with clinicopathological features could preoperatively predict LVI status. MATERIALS AND
methodsThis retrospective study enrolled 574 breast cancer patients who underwent MRI and surgery from January 2021 to December 2023. Patients were classified as LVI-positive (n=174) or LVI-negative (n=400) based on postoperative pathology. Breast edema on FS T2WI was scored from 1 to 4 (BES 1, no edema; BES 2, peritumoral edema; BES 3, prepectoral edema; and BES 4, subcutaneous edema). Univariate and multivariate binary logistic regression analyses were performed to identify risk factors associated with LVI. A clinicopathological model and a combined BES–clinicopathological model were constructed, and diagnostic performance was evaluated using the area under the receiver operating characteristic curve (AUC) and the DeLong test.
resultsMultivariate analysis revealed that BES and clinicopathological factors, including age, axillary lymph node metastasis, and tumor size, were independent predictors of LVI. Compared with BES 1, tumors with BES 2, BES 3, and BES 4 were associated with a 1.825-, 2.047-, and 4.341- fold increased LVI risk, respectively. The combined BES–clinicopathological model outperformed the clinicopathological model alone (AUC, 0.765 vs. 0.778; P<0.05). DISCUSSION: Higher BES was independently associated with increased LVI risk. The predictive model integrating BES with clinicopathological variables outperformed single-parameter models, suggesting that BES may provide complementary imaging biomarkers for assessing tumor aggressiveness. Validation in larger, multicenter cohorts is warranted.
conclusionFS T2WI-based BES combined with clinicopathological features may improve preoperative prediction of LVI in breast cancer and support individualized treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.